GLP-1 Shortage Status in 2026: What Is Available Now
Wegovy, Mounjaro, Zepbound, and Ozempic FDA shortage list updates and supply trends.
Key takeaways
The FDA officially declared both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) resolved on the national drug shortage list in 2025, ending the formal shortage that began in 2022.
All commercial doses of Wegovy and Zepbound are now listed as available by their manufacturers, though individual pharmacies still report intermittent regional gaps, especially for starter doses.
Compounded semaglutide and compounded tirzepatide lost their legal pathway under FDA section 503A/503B once the shortage ended; they are not FDA-approved finished products.
Pricing pressure from manufacturer direct-to-patient programs (LillyDirect, NovoCare) is now a bigger access issue than physical supply for most US patients in 2026.
If your pharmacy is out of a specific pen strength, the FDA recommends asking your prescriber about an in-stock dose of the same drug rather than switching molecules.
The Headline: FDA Shortage List Status in 2026
As of 2026, the four major branded GLP-1 receptor agonists used for type 2 diabetes and chronic weight management — , , , and — are all listed as resolved on the FDA Drug Shortage Database. Semaglutide (the molecule in Ozempic and Wegovy, made by Novo Nordisk) was declared resolved in February 2025. Tirzepatide (the molecule in Mounjaro and Zepbound, made by Eli Lilly) was declared resolved in late 2024 after a brief reinstatement following industry legal challenges.
That is the formal regulatory picture. The on-the-ground picture is more nuanced. Pharmacists across the US continue to report short, localized stockouts of specific pen strengths — particularly the lowest titration doses prescribers use to start new patients — even when manufacturers report adequate national supply. These are now classified as distribution gaps rather than a true shortage, which is an important legal distinction we explain below.
GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. This article tracks the public FDA shortage data and what major pharmacy chains and medical societies have reported through Q1 2026 so you have an accurate baseline before you talk to your prescriber.
How We Got Here: A Short Timeline of the GLP-1 Shortage
The shortage that defined GLP-1 access for nearly three years began in March 2022, when the FDA first added Wegovy (semaglutide 2.4 mg) to its shortage list. Mounjaro followed in late 2022, and Zepbound — approved by the FDA in November 2023 for chronic weight management — was added almost immediately after launch. By mid-2023, every commercial dose of every major GLP-1 was supply-constrained somewhere in the United States.
The shortage opened the door for compounding pharmacies. Under FDA sections 503A and 503B, licensed compounders are allowed to produce copies of drugs on the FDA shortage list. This is how and became widely available through telehealth platforms in 2023 and 2024 — they were legally permitted while the brand drugs were short.
Lilly's tirzepatide came off the FDA shortage list in October 2024, with a final resolution in December 2024 after the agency reviewed legal objections from the compounding industry. Novo Nordisk's semaglutide followed in February 2025. By spring 2025, both molecules had a defined wind-down window (60 days for 503A pharmacies, 90 days for 503B outsourcing facilities) after which mass compounding of these molecules was no longer legally protected.
Current Supply Status by Drug
Below is the public status of each major branded GLP-1 as reported by the FDA Drug Shortage Database and manufacturer supply pages as of Q1 2026. This is for general information — your local pharmacy stock is the only thing that determines whether your prescription can be filled today.
Across all four drugs, the lowest starter doses (0.25 mg semaglutide, 2.5 mg tirzepatide) are most likely to be temporarily out at any given pharmacy. The higher maintenance doses that established patients use are reported as the most consistently available, which is a reversal of the 2023 pattern when maintenance doses were the constrained SKUs.
Ozempic (semaglutide injection 0.25, 0.5, 1, 2 mg): All doses listed as available by Novo Nordisk; some local pharmacies report 2-7 day backorders on starter strengths.
Wegovy (semaglutide injection 0.25, 0.5, 1, 1.7, 2.4 mg): All doses listed as available; the new Wegovy oral semaglutide tablet (where approved) is reported as adequately supplied.
Mounjaro (tirzepatide injection 2.5, 5, 7.5, 10, 12.5, 15 mg): All KwikPen doses listed as available; vial format introduced by Lilly during the shortage remains a backup channel.
Zepbound (tirzepatide injection, same six strengths): All doses listed as available; LillyDirect Self Pay vials continue to ship to most US ZIP codes.
Why Your Pharmacy May Still Say 'Out of Stock'
There is a difference between a true FDA-declared shortage and a routine distribution gap. A true shortage means the manufacturer cannot meet total US demand. A distribution gap means the drug exists in adequate national volume, but a specific pharmacy hasn't received its allocation that week. In 2026, almost every reported GLP-1 stockout falls into the second category.
Wholesaler allocation algorithms still ration pen strengths to pharmacies based on historical fill volume. A pharmacy that didn't dispense much Zepbound in 2024 may receive small weekly shipments in 2026 even with national supply healthy. Independent pharmacies and rural locations are most affected. Pharmacy chains with central-fill operations (mail order from large warehouses) tend to have the most consistent inventory.
If your local pharmacy is out of a specific dose, the FDA's stated guidance during the wind-down period was to ask your prescriber about an in-stock dose of the same drug rather than switching molecules. Your prescriber may also be able to send the prescription to a different pharmacy or to a manufacturer direct-fulfillment program. Do not adjust your own dose or skip injections without medical guidance.
What Happened to Compounded GLP-1s in 2026
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished products. They were legally permitted under FDA sections 503A and 503B specifically because the branded drugs were on the FDA shortage list. Once both molecules were declared resolved in 2024-2025, that legal pathway closed for mass-market compounding of identical-strength copies.
The wind-down deadlines have now passed. 503A compounding pharmacies were required to stop dispensing compounded versions of these molecules within 60 days of resolution; 503B outsourcing facilities had 90 days. Telehealth platforms that built their business model on compounded GLP-1 have responded in three ways: shifting patients to branded prescriptions through manufacturer direct programs, offering compounded combinations (such as semaglutide plus B12 or NAD+) that argue for an individualized clinical justification, or exiting the category.
The FDA and several state pharmacy boards have explicitly warned that compounded copies of FDA-approved GLP-1s sold simply for convenience or cost are no longer legal. Compounded products may still be appropriate for individual patients with documented allergies to inactive ingredients in the branded version, but that is a narrow clinical scenario, not a substitute for the regular brand. If you are currently on a compounded GLP-1 through a telehealth platform, your prescriber should be transitioning you to a regulated alternative.
Affordability Has Replaced Availability as the Main Barrier
With physical supply largely restored, the biggest 2026 access issue for most US patients is price and insurance coverage. Cash list prices for Wegovy and Zepbound remain above $1,000 per month, though both manufacturers offer direct-to-patient self-pay programs (NovoCare and LillyDirect) that have meaningfully reduced out-of-pocket costs for patients without coverage.
Medicare Part D still does not cover GLP-1s when prescribed solely for chronic weight management, per the statutory exclusion. Coverage for type 2 diabetes (Ozempic, Mounjaro) is broader. Commercial insurance coverage for weight-management indications has tightened in 2025-2026, with more plans requiring documented BMI thresholds, prior authorization, and step therapy.
Trial data underpinning insurance decisions continues to grow. The STEP-1 trial reported about 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg, and the SURMOUNT-1 trial reported up to about 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg. Outcome trials — SELECT for semaglutide and SURPASS-CVOT for tirzepatide — are now part of the cardiovascular-risk evidence base that plans use to make coverage calls. Your prescriber and your benefits manager are the right team to confirm what your specific plan covers in 2026.
What to Do If You Can't Get Your Current GLP-1
If your specific drug or dose is unavailable at your usual pharmacy, do not stop or change your dose on your own. Abrupt discontinuation, double-dosing to catch up, or self-switching between semaglutide and tirzepatide all carry real clinical risks including gastrointestinal injury, rebound hyperglycemia, and blood-pressure swings. Your prescriber needs to be part of any change.
A reasonable sequence to discuss with your prescriber — not to act on alone — typically starts with confirming whether the gap is at your specific pharmacy or wider, then exploring same-drug strength substitutions before any switch between molecules. The numbered steps below summarize what major pharmacy associations have recommended during the post-shortage transition.
Call your pharmacy and ask whether the specific dose you need is on order, and when the next shipment is expected.
Ask your prescriber whether an in-stock strength of the same drug can bridge you (for example, holding at your current dose for an extra week instead of titrating up).
Have your prescription transferred to a different pharmacy, including manufacturer direct-fulfillment programs like NovoCare or LillyDirect for cash-pay patients.
If you are using a telehealth compounded GLP-1, ask whether your prescriber can transition you to a branded prescription now that the shortage has resolved.
Document any side effects, missed doses, or unexpected weight or glucose changes during a supply gap so your prescriber can adjust your plan.
Outlook for the Rest of 2026 and Beyond
Both Novo Nordisk and Eli Lilly have spent the last two years bringing additional manufacturing capacity online. New fill-finish plants in North Carolina, Indiana, and Europe are now contributing to global supply, and both companies have publicly stated that they expect production to outpace demand growth through at least 2027. Barring a new regulatory shock, a return to nationwide GLP-1 shortage is considered unlikely by industry analysts in the near term.
Several second-generation incretin drugs — including oral small-molecule GLP-1s and dual or triple agonist combinations like retatrutide — are in late-stage trials but are not commercially available in 2026. Their eventual launch, if approved, will likely expand the category rather than replace current options.
For now, the practical message for patients is simple: branded GLP-1s are generally obtainable in 2026 through a combination of standard pharmacies, mail-order, and manufacturer self-pay programs. Compounded copies of FDA-approved GLP-1s sold purely for cost reasons are no longer a legal pathway. Decisions about which medication is right for you, how to titrate, and how to handle any supply hiccups all belong with a licensed prescriber, not a comparison site.
Frequently asked questions
Is there still an Ozempic shortage in 2026?
No. The FDA Drug Shortage Database lists semaglutide — the active ingredient in Ozempic and Wegovy — as resolved as of February 2025, and that status has been maintained through Q1 2026. Some pharmacies still report short, local stockouts of specific pen strengths, but those are distribution gaps rather than a national shortage. If your pharmacy is out of your dose, the FDA recommends asking your prescriber about an in-stock strength of the same drug or transferring the prescription to a pharmacy with inventory.
Are Wegovy and Zepbound back in stock in 2026?
Yes. As of 2026, every commercial dose of Wegovy (semaglutide 2.4 mg and lower titration strengths) and every dose of Zepbound (tirzepatide 2.5 mg through 15 mg) is listed as available by Novo Nordisk and Eli Lilly. Both companies also operate direct-to-patient self-pay channels (NovoCare and LillyDirect) that ship to most US ZIP codes. Local stockouts at specific retail pharmacies still happen, but national supply is no longer the binding constraint for these drugs in 2026.
Can I still get compounded semaglutide or compounded tirzepatide in 2026?
Mass-market compounded copies of FDA-approved GLP-1s sold purely for convenience or cost are no longer legally protected in 2026. Compounded semaglutide and compounded tirzepatide were permitted under FDA sections 503A and 503B specifically because the branded drugs were on the FDA shortage list, and both molecules were declared resolved in 2024-2025. Compounded products are not FDA-approved as finished products. A compounded preparation may still be appropriate for narrow individual clinical situations, but that determination belongs to a licensed prescriber, not a telehealth marketing page.
Why is my pharmacy still out of my GLP-1 if the FDA says the shortage is over?
Wholesaler allocation algorithms still ration specific pen strengths based on a pharmacy's historical fill volume, so individual locations — especially independent and rural pharmacies — may receive small weekly shipments even when national supply is healthy. The lowest starter doses, like semaglutide 0.25 mg and tirzepatide 2.5 mg, are reported as the most frequently affected. This is classified as a distribution gap, not an FDA shortage. Mail-order pharmacies and manufacturer direct-fulfillment programs tend to have the most consistent inventory in 2026.
Should I switch from Ozempic to Mounjaro or vice versa because of supply?
Not on your own. Semaglutide and tirzepatide are different molecules with different mechanisms, different titration schedules, and different side-effect patterns. Switching between them is a medical decision that should be made by your prescriber based on your indication, your tolerance, your other medications, and your insurance coverage. In 2026, with both drug families generally available, supply alone is rarely a sufficient reason to switch. If you're considering it, raise the question with your prescriber and bring documentation of any access problems you've had at your current pharmacy.
How much weight loss can I expect from current GLP-1s based on trial data?
The STEP-1 trial of semaglutide 2.4 mg (Wegovy) reported about 14.9% mean body-weight reduction at 68 weeks in adults with obesity who did not have diabetes, compared with about 2.4% in the placebo group. The SURMOUNT-1 trial of tirzepatide reported up to about 20.9% mean weight reduction at 72 weeks at the 15 mg dose. These are averages — individual response varies widely, and people with type 2 diabetes generally lose less in trials. Your prescriber is the right person to set realistic expectations for your specific case.
Does insurance cover GLP-1s in 2026 now that the shortage is resolved?
Coverage in 2026 still depends on indication and plan. Medicare Part D continues to exclude GLP-1s when prescribed solely for chronic weight management, per the statutory exclusion that pre-dates these drugs. Type 2 diabetes coverage for Ozempic and Mounjaro is broader. Commercial insurance coverage for weight-management indications has tightened, with more plans requiring documented BMI thresholds, prior authorization, and step therapy. The end of the shortage did not change coverage policy directly, but it did make manufacturer self-pay programs more viable for uninsured patients.
We cite primary sources — FDA-approved prescribing information (DailyMed), ClinicalTrials.gov registry IDs, and peer-reviewed publications — over secondary commentary. Every medical claim is re-checked at least every 6 months. Spot something wrong? Tell us. See our full editorial policy.